Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Nivolumab |
Indication/Tumor Type | biliary tract cancer |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | biliary tract cancer | sensitive | Nivolumab | Phase II | Actionable | In a Phase II trial, baseline CD274 (PD-L1) expression was associated with increased median progression-free survival (PFS) in biliary tract cancer patients treated with Opdivo (nivolumab) compared to patients without CD274 (PD-L1) expression, with a median PFS of 19.8 months vs 2.4 months (P=0.0001) and 12-month PFS rate of 61% vs 5%, respectively (PMID: 36252287; NCT02829918). | 36252287 |
PubMed Id | Reference Title | Details |
---|---|---|
(36252287) | Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer. | Full reference... |